Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
NCT07923643, Not applicable, Not yet recruiting, Assiut University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain | ClinicalTrials.gov |
| NCT number | NCT07923643 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Assiut University | ClinicalTrials.gov |
| Conditions | Breast Cancer, Postoperative Pain, Chronic Postoperative Pain, Quality of Recovery | ClinicalTrials.gov |
| Interventions | Bupivacaine, Dexamethasone, Magnesium sulfate | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Quality of Recovery-15 score at 24 hours after surgery | 24 hours after surgery | Total score of the Quality of Recovery-15 questionnaire, ranging from 0 to 150, with higher scores indicating better postoperative recovery. | ClinicalTrials.gov |
| Secondary | Chronic Post-Mastectomy Pain | Through 6 months postoperatively | Assessing the presence or absence of chronic postoperative pain and its intensity using the Visual Analogue Scale (VAS)minimum value of 0, maximum value of 10, where higher scores mean a worse outcome | ClinicalTrials.gov |
| Secondary | Postoperative Pain Intensity | At arrival to Post- Anesthesia Care Unit (PACU) (0 hour), 2, 4, 6, 12, and 24 hours postoperatively. | Evaluating postoperative pain intensity using the Visual Analogue Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain). | ClinicalTrials.gov |
| Secondary | Total Postoperative Opioid Consumption | During the first 24 hours postoperatively | Measuring the total morphine consumption required by the patient as rescue analgesia. | ClinicalTrials.gov |
| Secondary | Time to First Request for Rescue Analgesia | Within the first 24 hours postoperatively | Recording the duration from the end of surgery until the patient first requests rescue analgesia (when Visual Analogue Scale (VAS)is 4 or more). | ClinicalTrials.gov |
| Secondary | Patient Satisfaction | At 24 hours postoperatively. | Evaluating patient satisfaction with postoperative pain management using a 5-point Likert scale (ranging from very dissatisfied to very satisfied)(minimum value of 1, maximum value of 5, where higher scores mean a better outcome). | ClinicalTrials.gov |
| Secondary | Block-Related Complications and Adverse Effects | Intraoperatively and throughout the 24-hour postoperative period. | Evaluating the overall incidence of any block-related complications or adverse events (including block failure, local anesthetic systemic toxicity, hematoma, infection, pneumothorax, nerve injury, or magnesium-related side effects), reported as the percentage of affected patients out of the total study population | ClinicalTrials.gov |
| Secondary | Incidence and Severity of Postoperative Nausea | During the first 24 hours postoperatively (Assessments will be performed at 2, 6, 12, and 24 hours postoperatively). | The incidence and severity of postoperative nausea will be assessed during the first 24 hours after surgery. Nausea severity will be measured using an 11-point Numerical Rating Scale (NRS), ranging from 0 (no nausea) to 10 (worst imaginable nausea). Assessments will be performed at 2, 6, 12, and 24 hours postoperatively. The incidence of nausea (NRS \> 0) and the severity scores at each assessment time will be recorded. | ClinicalTrials.gov |
| Secondary | Incidence and Frequency of Postoperative Vomiting | During the first 24 hours postoperatively (Assessments will be performed at 2, 6, 12, and 24 hours postoperatively). | The incidence and frequency of postoperative vomiting will be assessed during the first 24 hours after surgery. The occurrence of vomiting and the total number of vomiting episodes will be recorded at 2, 6, 12, and 24 hours postoperatively. The need for rescue antiemetic medication will also be documented. | ClinicalTrials.gov |
| Secondary | Intraoperative Fentanyl Requirements | Intraoperatively (during the surgical procedure). | Measuring the total intraoperative consumption of fentanyl. | ClinicalTrials.gov |
| Secondary | Heart rate | At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period). | Assessing heart rate values. | ClinicalTrials.gov |
| Secondary | Mean Arterial Pressure (MAP) | At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period). | Assessing Mean Arterial Pressure (MAP) values | ClinicalTrials.gov |
| Secondary | Oxygen Saturation (SpO2) | At baseline, after block, every 15 minutes intraoperatively, and at the end of surgery (extubation period). | Assessing peripheral oxygen saturation levels. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 16
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 7042372 | BACKGROUND | PubMed |
| 17540325 | BACKGROUND | PubMed |
| 18035760 | BACKGROUND | PubMed |
| 19606096 | BACKGROUND | PubMed |
| 19887534 | BACKGROUND | PubMed |
| 20146096 | BACKGROUND | PubMed |
| 20889650 | BACKGROUND | PubMed |
| 21641819 | BACKGROUND | PubMed |
| 22102509 | BACKGROUND | PubMed |
| 22102847 | BACKGROUND | PubMed |
| 23584408 | BACKGROUND | PubMed |
| 25528913 | BACKGROUND | PubMed |
| 27536077 | BACKGROUND | PubMed |
| 28741300 | BACKGROUND | PubMed |
| 33930470 | BACKGROUND | PubMed |
| 39393309 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)